Relationship between angiogenesis and grade of histologic differentiation in endometrial adenocarcinoma

The objective of the study was to quantify vessels and to relate them to the degree of histologic differentiation in endometrial adenocarcinoma. We studied 35 cases of which ten were G1, 13 G2 and 12 G3 adenocarcinomas. The control group consisted of 11 atrophic and 10 proliferative endometria. From each case two histologic sections were obtained: one for hematoxylin-eosin staining and the other for immunohistochemical study with anti-CD34. Vessel count was performed by morphometric study. Mean vessel count was 15.3 for G1; 19 for G2 and 22.7 for G3 adenocarcinomas; in the control group it was 11.6 for atrophic and 13.2 for proliferative endometria. Slightly differentiated adenocarcinoma presented greater angiogenesis than normal and well-differentiated carcinoma. In contrast, moderately differentiated carcinoma showed greater angiogenicity as related to normal endometrium, but did not differ from other tumoral endometria.

Angiogenesis; Adenocarcinoma; Endometrium

[1] Torloni H., Brumini R.: Registro de tumores, 1978, Brazil.

[2] Inca - Instituto Nacional Do Cancer: "Estimativa da incidencia e mortalidade por cancer no Brasil 1998". Rio de Janeiro, ProOnco/INCA, 1998, 18.

[3] Taxa de mortalidade segundo a Fundacao Oncocentro -www.fosp.saude.sp.gov.br/html/fr.dados.html-acesso em 14/12/2004.

[4] Disaia P.J., Creasman W.T., Boronow R.C., Blessing J.A.: "Risk factors and recurrent patterns in Stage I endometrial cancer". Am J. Obstet. Gynecol., 1985, 151, 1009.

[5] Góis N.M., Martins N.V., Abrao F.S., Rodrigues De Lima G., Alves A.C.: "Peritumorous lymph-vascular invasion, grade of histologic differentiation, and myometrial infiltration as prognostic factors of endometrial carcinoma". Rev. Paul. Med., 1993, 111, 385.

[6] Wakui S., Furusato M., ltoh T., Sasaki J., Akiyama A., Kinoshita I. et al.: "Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: A morphometric study". J. Pathol., 1992, 168, 257.

[7] Barnhill R.L., Fandrey K., Levy M.A., Mihm M.C., Hyman B.: "Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma". Lab. Invest., 1992, 67, 331.

[8] Horak E.R., Leek R., Klenk N., Lejeune S., Smith K. et al. "Angiogenesis, assessed by platelet/endothelial cell adhesion mo!ecule antibodies, as indicator of node metastases and survival in breast cancer". Lancet, 1992, 340, 1120.

[9] Bremer G.L., Tiebosch A.T.M.G., Van Der Putten H.W.H.M., Schouten HJ.A., Haan J. Arends J.W.: "Tumor angiogenesis: An independent prognostic parameter in cervical cancer". Am. J. Obstet. Gynecol., 1996, 174, 126.

[10] Sivridis E., Giatromanolaki A.: "New insights into the normal menstrual cycle-regulatory molecules". Histol. Histopathol., 2004, 19, 511.

[11] Abulafia O., Tries! W.E., Sherer D.M., Hansen C.C., Ghezzi F "Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma". Obstet. Gynecol., 1995, 86, 479.

[12] Salvesen H.B., Gulluoglu M.G., Stefansson I., Akslen L.A.: "Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas". APMIS, 2003, 111, 1011.

[13] Wagatsuma S., Konno R., Sato S., Yajima A: "Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma". Cancer, 1998, 82, 520.

[14] FIGO News: "Annual report on the results of treatment rn gynecological cancer". Int. J. Gynaecol. Obstet., 1989, 28, 189.

[15] Ramani P., Bradley NJ., Fletcher C.D.M.: "QBEND/10, a new monoclonal antibody to endothelium: assessment of its diagnostic utility in paraffin sections". Histopathology, 1990, 17, 237.

[16] Peek M.J., Markham R., Fraser I.S.: "Angiogenic activity in normal and dysfunctional uterine bleeding human endometrium; as measures by the chick chorioallantoic membrane assay". Exp. Toxic. Pathol., 1995, 47, 397.

[17] Mazurek A., Pierzynski P., Kuc P., Kopinski P., Terlikowski S., Niklinska W. et al.: "Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer". Neoplasma, 2004, 51, 193.

[18] Salvesen H.B., Iversen O.E., Akslen L.A.: "Independent prognostic importance of microvessel density in endometrial carcinoma". Br. J. Cancer, 1998, 77, 1140.

[19] Szymanski W., Formaniak J., Szymanski M., Grabiec M.: "Neoangiogenesis in immunohistochemical techniques as a prognostic factor in endometrial carcinoma". Ginekol. Pol., 2003, 74, 885.

[20] Folkman J.:'Tumor angiogenesis: Therapeutic implications". N. Engl. J. Med., 1971, 285, 1182.